Join Clinical Trials in Colorado

Browse Locations United States » Colorado

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (Study No. V212-001 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Matching placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 70 Years

Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years

Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012
Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix

Conditions: Herpes Simplex Type Two Infection; HIV Infections
Interventions: Drug: Valacyclovir; Drug: Placebo
Sponsors: University of Toronto; University of Toronto
Completed - verified March 2012
Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation

Condition: Kidney Transplant
Interventions: Biological: Zostavax (Live attenuated herpes zoster vaccine); Biological: Placebo vaccine
Sponsors: University of Alberta; University of Alberta
Recruiting - verified April 2012
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Conditions: Rubella; Varicella; Mumps; Measles
Interventions: Biological: MeMuRu-OKA (study vac); Biological: MMR, Varicella vacc (control)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes

Condition: Genital Herpes
Interventions: Drug: Famciclovir; Drug: Valacyclovir; Drug: Placebo matching famciclovir; Drug: Placebo matching valacyclovir
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified June 2011
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Condition: Herpes Simplex
Interventions: Biological: GSK208141; Biological: HavrixTM (investigational formulation); Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine

Condition: Herpes Simplex
Intervention: Biological: GSK208141 vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified September 2011
Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates

Condition: Herpes Simplex
Interventions: Drug: Acyclovir; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified October 2009
Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

Condition: Herpes Simplex
Interventions: Drug: Acyclovir; Drug: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified November 2009